免疫检查点抑制剂相关急性肾损伤:第34届ADQI共识会议报告
第34届急性疾病质量倡议(ADQI)共识会议于2024年9月召开,采用系统文献检索和改良Delphi法制定免疫检查点抑制剂相关急性肾损伤(ICI-AKI)的共识声明。观察性数据显示ICI治疗患者中AKI发生率高达20%,其中ICI-AKI约占2%-5%,急性小管间质性肾炎是最常见病理类型(活检中80%-90%)。共识提供了诊断和管理框架,支持特定患者谨慎进行ICI再挑战。
要点
- ICI治疗患者AKI发生率高达20%,ICI-AKI约占2%-5%,急性小管间质性肾炎占活检80%-90%。
- 肾活检是诊断金标准,尚无临床特征可靠区分ICI-AKI与其他原因AKI。
- 诊断后3天内早期使用糖皮质激素与更高肾脏恢复率相关,但最佳剂量和疗程未定。
核心结论
- ICI-AKI是癌症免疫治疗的重要且潜在可逆的并发症,共识声明为诊断和管理提供了框架。
- 支持在选定患者中谨慎进行ICI再挑战,并确定了未来研究优先方向。
研究设计与样本
- 国际多学科专家组于2024年9月召开第34届ADQI共识会议。
- 对PubMed进行系统文献检索,涵盖ICI-AKI的流行病学、机制、诊断、管理、再挑战和结局。
- 采用改良Delphi法,通过结构化讨论和投票制定共识声明。
主要发现
- 观察性数据显示接受ICI治疗的患者中AKI发生率高达20%,ICI-AKI约占2%-5%。
- 急性小管间质性肾炎是最常见病变,在80%-90%的活检中观察到,但肾小球疾病日益被认识。
- 诊断后3天内早期使用糖皮质激素与更高肾脏恢复率相关,但最佳剂量和疗程仍不确定。
- ICI再挑战患者中复发性ICI-AKI发生率低于20%。
关键数值与推荐
- 肾活检仍是诊断ICI-AKI的金标准。
- 新兴尿液、循环和影像生物标志物显示前景,但尚未准备好常规临床使用。
- 高危人群包括肾移植受者、自身免疫病患者或晚期CKD患者,需个体化多学科决策。
临床怎么用
- 对接受ICI治疗的患者应监测AKI,怀疑ICI-AKI时及时评估,肾活检用于确诊。
- 确诊ICI-AKI后考虑早期(3天内)启动糖皮质激素治疗以促进肾脏恢复。
- 对高危人群(肾移植、自身免疫病、晚期CKD)进行个体化多学科管理。
- 选定患者可谨慎进行ICI再挑战,再挑战后复发性ICI-AKI发生率低于20%。
局限性
- 证据主要来自观察性数据,缺乏随机对照试验。
- 糖皮质激素的最佳剂量和疗程尚不确定。
- 生物标志物尚未验证用于常规临床实践。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Immune checkpoint inhibitors (ICIs) have transformed cancer therapy but are associated with immune-related adverse events, including ICI-associated AKI (ICI-AKI). ICI-AKI presents diagnostic and management challenges and can influence decisions regarding immunosuppression and ICI rechallenge, with important implications for both kidney and cancer outcomes. An international, multidisciplinary panel convened at the 34th Acute Disease Quality Initiative (ADQI) consensus conference in September 2024. Systematic literature searches of PubMed were conducted to identify studies on the epidemiology, mechanisms, diagnosis, management, rechallenge, and outcomes of ICI-AKI. The meeting followed the established ADQI process and used a modified Delphi method to achieve consensus. Evidence was reviewed and appraised by workgroups, and consensus statements were developed through structured discussion and voting. Observational data suggest that AKI occurs in up to 20% of patients receiving ICIs, with ICI-AKI accounting for approximately 2%-5% of cases. Acute tubulointerstitial nephritis is the most common lesion, observed in 80%-90% of biopsies, although glomerular diseases are increasingly recognized. No clinical features reliably distinguish ICI-AKI from other causes of AKI, and kidney biopsy remains the diagnostic gold standard. Emerging urinary, circulating, and imaging biomarkers show promise but are not yet ready for routine clinical use. Early glucocorticoid initiation (within 3 days of ICI-AKI diagnosis versus >3 days after diagnosis) is associated with higher rates of kidney recovery, although optimal dosing and duration remain uncertain. Recurrent ICI-AKI occurs in fewer than 20% of patients undergoing ICI rechallenge. Management of high-risk populations, including kidney transplant recipients and patients with autoimmune disease or advanced CKD, requires individualized, multidisciplinary decision making. ICI-AKI is an important and potentially reversible complication of cancer immunotherapy; these consensus statements provide a framework for diagnosis and management, support cautious ICI rechallenge in selected patients, and identify priorities for future research.
引用
- Gupta S, Fenoglio R, Murakami N, et al. Immune Checkpoint Inhibitor-Associated Acute Kidney Injury: A Report from the 34th Acute Disease Quality Initiative (ADQI) Consensus Conference. J Am Soc Nephrol. 2026. PMID: 42536415. doi:10.1681/ASN.0000001232
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。